Gilead Sciences Inc. Posts Q2 Results, Able To Beat Earnings, Revenue Estimates
July 28, 2015 at 19:18 PM EDT
Despite projected declines in its Hep C drug, the outlook for GILD’s earnings remains positive. The consensus estimate saw a major jump between 60 and 90 days ago.
